Feasibility of ASL-based phMRI with a single dose of oral citalopram for repeated assessment of serotonin function

NeuroImage

Volumn 63, Issue 3, 2012, Pages 1695-1700

  Klomp, A ^a   Caan, M W A ^a   Denys, D ^a   Nederveen, A J ^a   Reneman, L ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

5 HT; Arterial spin labeling; Pharmacological MRI; Repeatability; SSRIs

Indexed keywords

CITALOPRAM; PLACEBO; SEROTONIN;

ABSENCE OF SIDE EFFECTS; AMYGDALOID NUCLEUS; ANTERIOR CINGULATE; ARTERIAL SPIN LABELING; ARTICLE; BRAIN BLOOD FLOW; BRAIN FUNCTION; BRAIN REGION; CAUDATE NUCLEUS; CONTROLLED STUDY; CROSSOVER PROCEDURE; EFFECT SIZE; FEMALE; FRONTAL GYRUS; GRAY MATTER; HIPPOCAMPUS; HUMAN; HUMAN EXPERIMENT; INFERIOR FRONTAL GYRUS; MEDICAL ASSESSMENT; MIDDLE FRONTAL GYRUS; NON INVASIVE MEASUREMENT; NORMAL HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; ORBITAL CORTEX; PRIORITY JOURNAL; PUTAMEN; RADIOLOGICAL PROCEDURES; RANDOMIZED CONTROLLED TRIAL; RELIABILITY; REPRODUCIBILITY; SENSITIVITY ANALYSIS; SEROTONINERGIC TRANSMISSION; SIGNAL PROCESSING; SINGLE DRUG DOSE; SUPERIOR FRONTAL GYRUS; TEST RETEST RELIABILITY; THALAMUS; VOLUNTEER;

ADULT; BRAIN; CITALOPRAM; FEASIBILITY STUDIES; FEMALE; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; REPRODUCIBILITY OF RESULTS; SEROTONIN; SEROTONIN UPTAKE INHIBITORS; SINGLE-BLIND METHOD; SPIN LABELS; YOUNG ADULT;

EID: 84866265899     PISSN: 10538119     EISSN: 10959572     Source Type: Journal    
DOI: 10.1016/j.neuroimage.2012.07.038     Document Type: Article

References (39)

1. Aguirre G.K., Zarahn E., D'Esposito M. The variability of human, BOLD hemodynamic responses. NeuroImage 1998, 8:360-369.
2. Anderson I.M., McKie S., Elliott R., Williams S.R., Deakin J.F. Assessing human 5-HT function in vivo with pharmacoMRI. Neuropharmacology 2008, 55:1029-1037.
3. Ashburner J. A fast diffeomorphic image registration algorithm. NeuroImage 2007, 38:95-113.
4. Aznavour N., Rbah L., Riad M., Reilhac A., Costes N., Descarries L., Zimmer L. A PET imaging study of 5-HT(1A) receptors in cat brain after acute and chronic fluoxetine treatment. NeuroImage 2006, 33:834-842.
5. Bland J.M., Altman D.G. Measurement error. BMJ 1996, 313:744.
6. Caceres A., Hall D.L., Zelaya F.O., Williams S.C., Mehta M.A. Measuring fMRI reliability with the intra-class correlation coefficient. NeuroImage 2009, 45:758-768.
7. Chalela J.A., Alsop D.C., Gonzalez-Atavales J.B., Maldjian J.A., Kasner S.E., Detre J.A. Magnetic resonance perfusion imaging in acute ischemic stroke using continuous arterial spin labeling. Stroke 2000, 31:680-687.
8. Chen Y., Wan H.I., O'Reardon J.P., Wang D.J., Wang Z., Korczykowski M., Detre J.A. Quantification of cerebral blood flow as biomarker of drug effect: arterial spin labeling phMRI after a single dose of oral citalopram. Clin. Pharmacol. Ther. 2011, 89:251-258.
9. Chen Y., Wang D.J., Detre J.A. Test-retest reliability of arterial spin labeling with common labeling strategies. J. Magn. Reson. Imaging 2011, 33:940-949.
10. Dalgaard L., Larsen C. Metabolism and excretion of citalopram in man: identification of O-acyl- and N-glucuronides. Xenobiotica 1999, 29:1033-1041.
11. Dijkhuizen R.M., Nicolay K. Magnetic resonance imaging in experimental models of brain disorders. J. Cereb. Blood Flow Metab. 2003, 23:1383-1402.
12. Gevers S., van Osch M.J., Bokkers R.P., Kies D.A., Teeuwisse W.M., Majoie C.B., Hendrikse J., Nederveen A.J. Intra- and multicenter reproducibility of pulsed, continuous and pseudo-continuous arterial spin labeling methods for measuring cerebral perfusion. J. Cereb. Blood Flow Metab. 2011, 31:1706-1715.
13. Golay X., Hendrikse J., Lim T.C. Perfusion imaging using arterial spin labeling. Top. Magn Reson. Imaging 2004, 15:10-27.
14. Golay X., Petersen E.T., Hui F. Pulsed star labeling of arterial regions (PULSAR): a robust regional perfusion technique for high field imaging. Magn. Reson. Med. 2005, 53:15-21.
15. Hu X.Z., Rush A.J., Charney D., Wilson A.F., Sorant A.J., Papanicolaou G.J., Fava M., Trivedi M.H., Wisniewski S.R., Laje G., Paddock S., McMahon F.J., Manji H., Lipsky R.H. Association between a functional serotonin transporter promoter polymorphism and citalopram treatment in adult outpatients with major depression. Arch. Gen. Psychiatry 2007, 64:783-792.
16. Hwang L.C., Chang C.J., Liu H.H., Kao H.C., Lee S.Y., Jan M.L., Chen C.C. Imaging the availability of serotonin transporter in rat brain with 123I-ADAM and small-animal SPECT. Nucl. Med. Commun. 2007, 28:615-621.
17. Klomp A., Tremoleda J.L., Wylezinska M., Nederveen A.J., Feenstra M., Gsell W., Reneman L. Lasting effects of chronic fluoxetine treatment on the late developing rat brain: age-dependent changes in the serotonergic neurotransmitter system assessed by pharmacological MRI. NeuroImage 2012, 59:218-226.
18. Kronenberg S., Apter A., Brent D., Schirman S., Melhem N., Pick N., Gothelf D., Carmel M., Frisch A., Weizman A. Serotonin transporter polymorphism (5-HTTLPR) and citalopram effectiveness and side effects in children with depression and/or anxiety disorders. J. Child Adolesc. Psychopharmacol. 2007, 17:741-750.
19. Leslie R.A., James M.F. Pharmacological magnetic resonance imaging: a new application for functional MRI. Trends Pharmacol. Sci. 2000, 21:314-318.
20. Lotrich F.E., Pollock B.G., Ferrell R.E. Polymorphism of the serotonin transporter: implications for the use of selective serotonin reuptake inhibitors. Am. J. Pharmacogenomics. 2001, 1:153-164.
21. Luo F., Schmidt K.F., Fox G.B., Ferris C.F. Differential responses in CBF and CBV to cocaine as measured by fMRI: implications for pharmacological MRI signals derived oxygen metabolism assessment. J. Psychiatr. Res. 2009, 43:1018-1024.
22. Mathew R.J., Wilson W.H. Substance abuse and cerebral blood flow. Am. J. Psychiatry 1991, 148:292-305.
23. McGraw K.O., Wong S.P. Forming Inferences About Some Intraclass Correlation Coefficients 1996, 30-46.
24. McKie S., Del-Ben C., Elliott R., Williams S., del Vai N., Anderson I., Deakin J.F. Neuronal effects of acute citalopram detected by pharmacoMRI. Psychopharmacology (Berl) 2005, 180:680-686.
25. Mendoza L., Hajduch M., Kekulova H., Svobodova X., Mihal V., Svoboda M. Bioequivalence of two brands of citalopram 40mg tablets after single oral administration to healthy volunteers. Biomed. Pap. Med. Fac. Univ Palacky. Olomouc. Czech. Repub. 2005, 149:169-172.
26. Paterson L.M., Kornum B.R., Nutt D.J., Pike V.W., Knudsen G.M. 5-HT radioligands for human brain imaging with PET and SPECT. Med.Res.Rev 2011 Jun 14, [Epub ahead of print]. 10.1002/med.20245.
27. Saulin A., Savli M., Lanzenberger R. Serotonin and molecular neuroimaging in humans using PET. Amino. Acids 2012, 42:2039-2057.
28. Schouw M.L., Gevers S., Caan M.W., Majoie C.B., Booij J., Nederveen A.J., Reneman L. Mapping serotonergic dysfunction in MDMA (ecstasy) users using pharmacological MRI. Eur. Neuropsychopharmacol. 2011.
29. Schwarz A.J., Gozzi A., Reese T., Bifone A. In vivo mapping of functional connectivity in neurotransmitter systems using pharmacological MRI. NeuroImage 2007, 34:1627-1636.
30. Seifritz E., Baumann P., Muller M.J., Annen O., Amey M., Hemmeter U., Hatzinger M., Chardon F., Holsboer-Trachsler E. Neuroendocrine effects of a 20-mg citalopram infusion in healthy males. A placebo-controlled evaluation of citalopram as 5-HT function probe. Neuropsychopharmacology 1996, 14:253-263.
31. Shah Y.B., Marsden C.A. The application of functional magnetic resonance imaging to neuropharmacology. Curr. Opin. Pharmacol. 2004, 4:517-521.
32. Shrout P.E., Fleiss J.L. Intraclass correlations: uses in assessing rater reliability. Psychol. Bull. 1979, 86:420-428.
33. Smith G.S., Ma Y., Dhawan V., Gunduz H., Carbon M., Kirshner M., Larson J., Chaly T., Belakhleff A., Kramer E., Greenwald B., Kane J.M., Laghrissi-Thode F., Pollock B.G., Eidelber D. Serotonin modulation of cerebral glucose metabolism measured with positron emission tomography (PET) in human subjects. Synapse 2002, 45:105-112.
34. Talairach J., Tournoux P. Co-planar Stereotaxic Atlas of the Human Brain 1988, Thieme, New York.
35. van Vliet I.M., de Beurs E. The MINI-International Neuropsychiatric Interview. A brief structured diagnostic psychiatric interview for DSM-IV en ICD-10 psychiatric disorders. Tijdschr. Psychiatr. 2007, 49:393-397.
36. Wang D.J., Chen Y., Fernandez-Seara M.A., Detre J.A. Potentials and challenges for arterial spin labeling in pharmacological magnetic resonance imaging. J. Pharmacol. Exp. Ther. 2011, 337:359-366.
37. Wang Y., Saykin A.J., Pfeuffer J., Lin C., Mosier K.M., Shen L., Kim S., Hutchins G.D. Regional reproducibility of pulsed arterial spin labeling perfusion imaging at 3T. NeuroImage 2011, 54:1188-1195.
38. Wolf R.L., Detre J.A. Clinical neuroimaging using arterial spin-labeled perfusion magnetic resonance imaging. Neurotherapeutics 2007, 4:346-359.
39. Zhang Z., Andersen A.H., Ai Y., Loveland A., Hardy P.A., Gerhardt G.A., Gash D.M. Assessing nigrostriatal dysfunctions by pharmacological MRI in parkinsonian rhesus macaques. NeuroImage 2006, 33:636-643.